Short Interest in Valneva SE (NASDAQ:VALN) Decreases By 23.7%

Valneva SE (NASDAQ:VALN – Get Rating) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 48,000 shares, a decrease of 23.7% from the June 30th total of 62,900 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is currently 1.8 days. Approximately 0.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Kepler Capital Markets lowered shares of Valneva from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th.

Valneva Trading Down 5.3 %

Shares of VALN stock opened at $19.16 on Tuesday. Valneva has a 52-week low of $13.71 and a 52-week high of $67.84. The business’s fifty day moving average is $21.68 and its 200 day moving average is $28.58. The company has a current ratio of 1.50, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32.

Valneva (NASDAQ:VALN – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.38. The business had revenue of $24.51 million for the quarter, compared to the consensus estimate of $22.51 million. Equities research analysts forecast that Valneva will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

A number of hedge funds and other institutional investors have recently bought and sold shares of VALN. Bank of America Corp DE bought a new stake in shares of Valneva during the 1st quarter worth $858,000. Jane Street Group LLC raised its position in Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after purchasing an additional 7,664 shares in the last quarter. Finally, Alps Advisors Inc. bought a new stake in Valneva during the fourth quarter worth about $3,369,000. Hedge funds and other institutional investors own 0.21% of the company’s stock.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.